TickerFacts.

Company research / DNLI

Denali Therapeutics Inc. (DNLI)

Build a valuation ↗↓ Download CSV

CIK 0001714899 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Denali Therapeutics Inc. reported revenue of $0. Over the twelve months to 2026-06-30, revenue was $3.60M.

Key ratios (year ended 2025-12-31)

-50.6%
Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-09-09

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$3.60M$0$0$330.53M$105.06M$48.66M$335.56M$26.32M$129.10M$0$0
R&D Expense$400.72M$418.78M$396.44M$423.88M$358.73M$265.35M$212.62M$193.38M$143.18M$74.46M$75.70M
Operating Income-$542.70M-$555.34M-$487.34M-$196.70M-$340.74M-$295.75M$62.72M-$213.18M-$46.37M-$90.14M-$87.43M
Depreciation & Amortization$12.23M$11.18M$7.79M$16.73M$10.38M$8.59M$8.53M$7.99M$7.42M$3.08M$1.47M
EBITDA-$530.47M-$544.16M-$479.55M-$179.97M-$330.36M-$287.16M$71.25M-$205.19M-$38.96M-$87.06M-$85.96M
Net Income-$511.45M-$512.54M-$422.77M-$145.22M-$325.99M-$290.58M$71.14M-$197.61M-$36.24M-$88.19M-$86.65M
EPS (Diluted)n/a-$2.97-$2.57-$1.06-$2.60-$2.39$0.63-$2.07-$0.39n/an/a
Total Assets$1.16B$1.14B$1.37B$1.15B$1.46B$1.40B$1.60B$553.23M$661.98M$486.72Mn/a
Total Liabilities$322.78M$131.09M$144.50M$122.96M$417.81M$441.87M$453.75M$158.34M$115.14M$20.93Mn/a
Shareholders' Equity$835.18M$1.01B$1.23B$1.03B$1.04B$962.29M$1.15B$394.89M$546.85M$465.80M-$94.15M
Cash & Equivalents$201.53M$205.33M$174.96M$127.11M$218.04M$293.48M$507.14M$79.45M$77.12M$218.38M$39.85M
Operating Cash Flow-$434.04M-$412.60M-$347.69M-$357.99M-$244.72M-$211.39M$416.15M-$151.58M$50.12M-$76.64M-$71.91M
Capital Expenditures$3.42M$9.50M$15.91M$12.94M$17.83M$8.50M$3.10M$17.92M$3.39M$2.88M$6.13M
Free Cash Flow-$437.46M-$422.10M-$363.61M-$370.93M-$262.55M-$219.89M$413.06M-$169.50M$46.72M-$79.51M-$78.04M
Shares Outstanding159.76M156.18M144.22M138.39M135.97M122.28M120.53M96.19M94.66M87.48Mn/a
Weighted Average Diluted Sharesn/a172.65M164.47M137.37M125.53M121.52M112.70M95.61M92.62Mn/an/a
EPS (Basic)n/a-$2.97-$2.57-$1.06-$2.60-$2.39$0.65-$2.07-$0.39n/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView